The sales of biopharmaceuticals and biotherapy from only Humira, Remicade, and Enbrel are over $18 billion in US in 2015. Protein therapy is expected to make about $250 billion in savings for US over the next 10 years.
To apply personalised medicine, as a customization of health care to individual patients, through linking personal diagnostics, can increase the effectiveness of the prescribed treatment regimen and to minimise their adverse effects.
Inhalers are widely used to treat chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Several 100 millions of patients worldwide rely on pressurised metered dose inhalers (pMDIs) or dry-powder inhalers (DPIs) to manage their condition and ensure a good quality of life.
The Actinobacteria are important producers of approved drugs (>$1 billion dollars in 2016) but low yields of most natural products are a significant barrier to drug discovery, development and commercialisation.